Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: A phase II study

Gynecologic Oncology

Volumn 95, Issue 1, 2004, Pages 165-172

  Pectasides, Dimitrios ^a,c   Pectasides, Melina ^b   Farmakis, Dimitrios ^b   Gaglia, Asimina ^b   Koumarianou, Anna ^a   Nikolaou, Maria ^b   Koumpou, Maria ^b   Kountourakis, Panteleimon ^a   Papaxoinis, Georgios ^a   Mitrou, Panagiota ^a   Economopoulos, Theofanis ^a   Raptis, Sotirios A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b METAXA CANCER HOSPITAL   (Greece)

^c Gravias 5B   (Greece)

Author keywords

5 Fluorouracil; Chemotherapy; FOLFOX 4; Ovarian cancer; Oxaliplatin; Platinum resistant

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PLATINUM DERIVATIVE; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SKIN MANIFESTATION; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; PROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 4644254283     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.06.029     Document Type: Article

References (48)

1. M. Markman, R. Rothman, and T. Hakes Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J. Clin. Oncol. 9 1991 389 393
2. R.F. Ozols Treatment of recurrent ovarian cancer: increasing options - "Recurrent" results J. Clin. Oncol. 15 1997 2177 2180
3. P. Sabbatini, and D. Spriggs Salvage therapy for ovarian cancer Oncology (Huntingt) 12 1998 833 843
4. R.F. Ozols Update of the NCCN ovarian cancer practice guidelines Oncology (Huntingt) 11 1997 95 105
5. L. Pendyala, and P.J. Creaven In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin Cancer Res. 53 1993 5970 5976
6. F. Levi, J.L. Misset, and S. Brienza A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer Cancer 69 1992 893 900
7. P.M. Fracasso, J.A. Blessing, and M.A. Morgan Phase II study of oxaliplatin in platinum-resistant and refractory ovarian cancer: a gynecologic group study J. Clin. Oncol. 21 2003 2856 2859
8. M.J. Piccart, J.A. Green, and A.J. Lacave Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group J. Clin. Oncol. 18 2000 1193 1202
9. P. Soulie, A. Bensmaine, and C. Garrino Oxaliplatin/cisplatin (l-OHP/CDDP) combination in heavily pretreated ovarian cancer Eur. J. Cancer 33 1997 1400 1406
10. P. Chollet, M.A. Bensmaine, and S. Brienza Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer Ann. Oncol. 7 1996 1065 1070
11. C. Sessa, W.W. ten Bokkel Huinink, and A. du Bois Oxaliplatin in ovarian cancer Ann. Oncol. 10 Suppl. 1 1999 55 57
12. M. Alvarez, W. Ortuzar, and O. Rixe Cross-resistance patterns of cell lines selected with platinum suggest differences in the activities and mechanisms of resistance of platinum analogues (abstract) Proc. Annual Meet. Am. Assoc. Cancer Res. 35 1994 439
13. A.F. Sobrero, C. Aschele, and A.P. Guglielmi Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer Clin. Cancer Res. 1 1995 955 960
14. R.M. Evans, J.D. Laskin, and M.T. Hakala Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil Cancer Res. 41 1981 3288 3295
15. J.H. Doroshow, P. Multhauf, and L. Leong Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy J. Clin. Oncol. 8 1990 491 501
16. J.J. Lokich, J.D. Ahlgren, and J.J. Gullo A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study J. Clin. Oncol. 7 1989 425 432
17. M. Prefontaine, J.T. Donovan, J.L. Powell, and L. Buley Treatment of refractory ovarian cancer with 5-fluorouracil and leucovorin Gynecol. Oncol. 61 1996 249 252
18. R.J. Morgan Jr., J. Speyer, and J.H. Doroshow Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels Gynecol. Oncol. 58 1995 79 85
19. K.Y. Look, H.B. Muss, J.A. Blessing, and M. Morris A phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study Am. J. Clin. Oncol. 18 1995 19 22
20. J.T. Kamphuis, M.C. Huider, and G.J. Ras High-dose 5-fluorouracil and leucovorin as second-line chemotherapy in patients with platinum-resistant epithelial ovarian cancer Cancer Chemother. Pharmacol. 37 1995 190 192
21. H.J. Long III, R.A. Nelimark, and J.Q. Su Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma Gynecol. Oncol. 54 1994 180 183
22. E. Raymond, C. Buquet-Fagot, and S. Djelloul Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers Anticancer Drugs 8 1997 876 885
23. C. Aschele, A. Sobrero, M.A. Faderan, and J.R. Bertino Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules Cancer Res. 52 1992 1855 1864
24. M.J. Piccart, E. Raymond, and M. Aapro Cytotoxic agents with activity in breast cancer patients previously exposed to anthracyclines: current status and future prospects Eur. J. Cancer 31A Suppl. 7 1995 S1 S10
25. J.L. Misset, Y. Kidani, and J. Gastiabaru Oxaliplatinum (l-OHP); experimental and clinical studies S.D. Howell Platinum and other metal coordination compounds in cancer chemotherapy 1991 Plenum New York 369 375
26. R.M. Goldberg, D.J. Sargent, R.F. Morton, C.S. Fuchs, R.K. Ramanathan, and S.K. Williamson A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer J. Clin. Oncol. 22 2004 23 30
27. D. Pectasides, M. Pectasides, and D. Farmakis Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: a phase II study Ann. Oncol. 14 2003 537 542
28. R. Simon Optimal two-stage designs for phase II clinical trials Control Clin. Trials 10 1989 1 10
29. World Health Organization WHO handbook for reporting results of cancer treatment (WHO Offset Publication No. 48) 1979 World Health Organization Geneva, Switzerland
30. E.L. Kaplan, and P. Meier Non-parametric estimation for incomplete observation J. Am. Stat. Assoc. 53 1958 457 481
31. A. Latorre, M. De Lena, and A. Catino Epithelial ovarian cancer: second and third line chemotherapy (review) Int. J. Oncol. 21 2002 179 186
32. W. Ten Bokkel Huinink, M. Gore, and J. Carmichael Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J. Clin. Oncol. 15 1997 2183 2193
33. J.D. Shapiro, M.J. Millward, and D. Rischin Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel Gynecol. Oncol. 63 1996 89 93
34. D. Tobias, A. Astrow, J. Koulos, F. Muggia, C. Runowicz, and J. Mandeli A Phase I trial of gemcitabine and doxil for recurrent epithelial ovarian cancer: a New York Gynecologic Oncology Group (NYGOG) Study (Abstract) Proc. Am. Soc. Clin. Oncol. 18 1999 385a [abstract 1488]
35. P.G. Rose, J.A. Blessing, A.R. Mayer, and H.D. Homesley Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group Study J. Clin. Oncol. 16 1998 405 410
36. G. Aravantinos, M.A. Dimopoulos, and P. Kosmidis Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancer Ann. Oncol. 11 2000 607 612
37. G. Bolis, F. Parazzini, and G. Scarfone Paclitaxel vs. epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer Gynecol. Oncol. 72 1999 60 64
38. J.A. Ledermann On behalf of ICON and AGO Collaborators. Randomised trial of paclitaxel in combination with platinum chemotherapy versus platinum-based chemotherapy in the treatment of relapsed ovarian cancer (ICON4/OVAR 2.2) Proc. Am. Soc. Clin. Oncol. 22 2003 446 [abstract 1794]
39. T. Andre, M.A. Bensmaine, and C. Louvet Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen J. Clin. Oncol. 17 1999 3560 3568
40. E. Raymond, S.G. Chaney, A. Taamma, and E. Cvitkovic Oxaliplatin: a review of preclinical and clinical studies Ann. Oncol. 9 1998 1053 1071
41. H. Bleiberg, and A. de Gramont Oxaliplatin plus 5-fluorouracil: clinical experience in patients with advanced colorectal cancer Semin. Oncol. 25 2 Suppl. 5 1998 32 39
42. S. Brienza, M.A. Bensmaine, and P. Soulie Oxaliplatin added to 5-fluorouracil-based therapy (5-FU +/- FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program Ann. Oncol. 10 1999 1311 1316
43. E.A. Eisenhauer, J.B. Vermorken, and M. van Glabbeke Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients Ann. Oncol. 8 1997 963 968
44. A. Cesano, S.R. Lane, and R. Poulin Stabilization of disease as a useful predictor of survival following second-line chemotherapy in small cell lung cancer and ovarian cancer patients Int. J. Oncol. 15 1999 1233 1238
45. S. Faivre, S. Kalla, and E. Cvitkovic Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: an investigator-originated compassionate-use experience Ann. Oncol. 10 1999 1125 1128
46. F. Recchia, S. De Filippis, and G. Saggio Phase I study of liposomal doxorubicin and oxaliplatin as salvage chemotherapy in advanced ovarian cancer Anticancer Drugs 14 2003 633 638
47. S. Kakolyris, C. Kouroussis, and M. Koukourakis A dose-escalation study of oxaliplatin and vinorelbine in patients with advanced solid tumors Oncology 63 2002 213 218
48. L. Zelek, P. Cottu, and M. Tubiana-Hulin Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients J. Clin. Oncol. 20 2002 2551 2558